MentalHealthDaily

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Gray Matter Abnormalities in Major Depression & Social Anxiety (2023 Analysis)

by GLOOM

Major depressive disorder (MDD) and social anxiety disorder (SAD) are two of the most prevalent mental health issues facing society today. They often occur together, challenging both patients and healthcare providers. Recent neuroimaging studies have begun to shed light on the unique and overlapping characteristics of these disorders, offering new insights into their complex neurobiology. …

Psychobiotic “Lactobacillus plantarum” (JYLP-326) for Test Anxiety in Students (2023 Study)

by GLOOM

Test anxiety among college students is a significant concern, affecting their mental and physical well-being. A new study suggests that a probiotic/psychobiotic intervention (Lactobacillus plantarum) could significantly alleviate anxiety, depression, and insomnia, with changes observed in the gut microbiota and fecal metabolites. Highlights: Prevalence of Test Anxiety: 20%-40% of college students experience test anxiety, often …

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

by GLOOM

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …

Gamification for Mental Health & Treatment of Psychiatric Disorders

by GLOOM

In recent years, gamification has risen as a groundbreaking strategy to enhance mental health treatments and boost patient engagement. Gamification’s roots date back to games like Dance Dance Revolution in 1998, which intertwined physical activity with gaming fun. Today, an array of games and apps like Nike+ and SuperBetter are designed not just for physical …

Lateral Habenula & Depression: The Anti-Reward Center (Mechanisms & Antidepressant Treatments)

by GLOOM

Depression is a complex and multifaceted disorder affecting millions worldwide. Emerging evidence suggests the lateral habenula, a small brain region, plays a crucial role in depression’s development and persistence. By influencing neurotransmitter systems and interacting with stress pathways, the lateral habenula’s dysfunction may lead to the classic symptoms of depression. Highlights: The lateral habenula is …